April 24, 2024

Genovis Annual Report 2023 published

Regulatory

Genovis 2023 Annual Report is now available in Swedish and English at our website.

To read or download the annual report in Swedish, go to:

https://investor.genovis.com/wp-content/uploads/Genovis_AR_2023_Sv.pdf

To read or download the annual report in English, go to:

https://investor.genovis.com/wp-content/uploads/Genovis_AR_2023_En.pdf

For more information, please contact:

Fredrik Olsson, CEO, Genovis AB

T+46 (0)70 276 46 56

E: fredrik.olsson@genovis.com

Genovis’ business concept is to apply its knowledge and customer driven innovation to design and provide tools for the development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes™ all over the world in innovative product formats that facilitate development and quality control of biological drugs.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (US). Genovis shares are listed on Nasdaq First North Growth Market and Carnegie Investment Bank AB (publ) is the Company’s Certified Adviser, email: certifiedadviser@carnegie.se

This is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.

Press Release _annual report_2023

Genovis_AR_2023_En